Zijie Xu

ORCID: 0009-0008-7610-5366
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atmospheric chemistry and aerosols
  • Air Quality and Health Impacts
  • Intermetallics and Advanced Alloy Properties
  • Monoclonal and Polyclonal Antibodies Research
  • Gut microbiota and health
  • Environmental Toxicology and Ecotoxicology
  • Aquatic Ecosystems and Phytoplankton Dynamics
  • Aerosol Filtration and Electrostatic Precipitation
  • Cancer Immunotherapy and Biomarkers
  • Solar-Powered Water Purification Methods
  • Membrane Separation Technologies
  • Constructed Wetlands for Wastewater Treatment
  • Microbial Community Ecology and Physiology
  • Plant-Microbe Interactions and Immunity
  • Thermal properties of materials
  • Atmospheric Ozone and Climate
  • Air Quality Monitoring and Forecasting
  • Lung Cancer Research Studies
  • Coastal wetland ecosystem dynamics
  • Pharmaceutical and Antibiotic Environmental Impacts
  • Advanced Thermoelectric Materials and Devices

Huaiyin Normal University
2025

University of Hong Kong
2024

Hong Kong University of Science and Technology
2024

Jinan University
2021-2022

Xinqiao Hospital
2022

Army Medical University
2022

Macrolide pollution has attracted a great deal of attention because its ecotoxic effects on microalgae, but the role phycospheric bacteria under antibiotic stress remains unclear. This study explored toxic erythromycin (ERY) growth and nitrogen metabolism Auxenochlorella pyrenoidosa; then, it analyzed predicted composition ecological function microalgae ERY stress. We found that 0.1, 1.0, 10 mg/L inhibited chlorophyll gradually showed enhanced abilities over course 21 days. As exposure time...

10.3390/plants14010121 article EN cc-by Plants 2025-01-03

Penpulimab is a novel humanized IgG1 mAb that blocks PD-1 binding to PD-L1, engineered eliminate FcγR and ADCC/ADCP completely. AK105-302 1:1 randomized, double-blind, placebo-controlled, multicenter, phase III trial compare penpulimab or placebo plus carboplatin paclitaxel as first-line treatment for locally advanced metastatic squamous NSCLC. The stratification factors included PD-L1 gender. Eligible pts were randomized receive 200 mg chemotherapy every 3 weeks four cycles, followed by...

10.1016/j.iotech.2022.100164 article EN cc-by-nc-nd Immuno-Oncology Technology 2022-12-01
Coming Soon ...